Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy.;Efficacité et rémission durables après traitement par imatinib mésylate pour une cardiomyopathie éosinophilique à transcrit FIP1L1-PDGFRA négatif

Annales Pharmaceutiques Francaises

Volumn 69, Issue 5, 2011, Pages 277-281

  Sekkach, Y ^a   Mekouar, F ^a   Jira, M ^a   Elqatni, M ^a   Elomri, N ^a   Fatihi, J ^a   Badaoui, M ^a   Hammi, S ^a   Smaali, J ^a   El Khattabi, A ^a   Amezyane, T ^a   Abouzahir, A ^a   Ghafir, D ^a  

^a MILITARY HOSPITAL MOHAMMED V   (Morocco)

Author keywords

Cardiomyopathy; Eosinophilia; FIP1L1 PDGFRA transcript; Hypereosinophilic syndrome; Imatinib mesylate

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

ARTICLE; CASE REPORT; CONGESTIVE CARDIOMYOPATHY; FUSION GENE; HUMAN; HYPEREOSINOPHILIC SYNDROME; RELAPSE;

ADULT; ASTHMA; ELECTROCARDIOGRAPHY; EOSINOPHILS; FEMALE; HUMANS; HYPEREOSINOPHILIC SYNDROME; HYPERTENSION; HYPERTENSION, PULMONARY; LEUKOCYTE COUNT; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PROTEASE INHIBITORS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 80052877033     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2011.07.004     Document Type: Article

References (16)

1. Cools J., De Angelo D.J., Gotlib J., Slover E.H., Legare R.D., Cortes J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Eng J Med 2003, 348:1199-1200.
2. Klion A.D., Bochner B.S., Gleich G.J. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin immunol 2006, 117:1292-1302.
3. Simon H.U., Plotz S.G., Dummer R., Blaser K. Abnormal clones of T cells producing interleukine 5 in idiopathic eosinophilia. N Eng J Med 1999, 341:1112-1120.
4. Chusid M.J., Dale D.C., West B.C., Wolff S.M. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975, 54:1-27.
5. Simon H.U., Rothenberg M.E., Bochner B.S., Weller P.F., Wardlaw A.J., Wechsler M.E., et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010, 126:45-49.
6. Weller P., Bubley G.J. The idiopathic hypereosinophilic syndrome. Blood 1994, 83:2759-2779.
7. Roufosse F., Cogan E., Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med 2003, 54:169-184.
8. Ogbogu P.U., Bochner B.S., Butterfield J.H., Gleich G.J., Huss-Marp J., Kahn J.E., et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009, 124:1319-1325. e3.
9. Ommen S.R., Seward J.B., Tajik A.J. Clinical and echocardiographic features of hypereosinophilic syndromes. Am J Card 2000, 86:110-113.
10. Fourcarde L., Heno P., Nguyen Huy Thuy, et al. Le cœur et l'éosinophile. Med Trop 1998, 58:465-470.
11. Plastiras S.C., Economopoulos N., Kelekis N.L., Tzelepis G.E. Magnetic resonance imaging of the heart in a patient with hypereosinophilic syndrome. Am J Med 2006, 119:130-132.
12. Alter P., Maisch B. Endomyocardial fibrosis in Churg-Strauss syndrome assessed by cardiac magnetic resonance imaging. Inter J Card 2006, 108:112-113.
13. Gotlib J., Cools J., Malone J.M., Schrier S.L., Gilliland D.G., Coutre S.E. The FIP1L1-PDGFRA fusion tyrosine kinase in hypereosinophilic syndrome, and chronic eosinophilic leukaemia: implications for diagnosis, classification and management. Blood 2004, 103:2879-2891.
14. Elling C., Erben P., Walz C., Frickenhaus M., Schemionek M., Stehling M. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 2011, 117:2935-2943.
15. Kerkela R., Grazette L., Yacobi R. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006, 12(8):908-916.
16. Schaller J.L., Burkland G.A. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med 2001, 3:9.